Kelun Biotech Bio-B core product approved for new indications

2025-03-11 00:22:20

Kelun Biotech Bio-B announced that its core product, sac-TMT, has recently been approved by the National Medical Products Administration for the treatment of EGFR-mutated non-small cell lung cancer. This approval makes sac-TMT the world's first TROP2 antibody-drug conjugate (ADC) approved for lung cancer, marking an important progress in the company's anti-cancer drug field.

anti-cancer drug

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Xi'an technology companies have achieved AI-customized organs and made breakthrough progress in the fields of 3D bioprinting and bionic tissue engineering
                            2025-03-19

                                    Xiaomi Group (01810.HK): Sales costs increased 35.5% from RMB 213.5 billion for the year ended December 31, 2023 to RMB 289.3 billion for the year ended December 31, 2024.
                            2025-03-18

                                    Huawei's Wang Tao: China's government and enterprise revenue growth to exceed 25% in 2024
                            2025-03-20

                                    A-share closing review: Shanghai Composite Index fluctuated slightly and fell by 0.1%, with defensive sectors such as banks, coal and electricity leading the gains
                            2025-03-19

                                    Liu Qiangdong appeared at the Hong Kong University of Science and Technology and visited several artificial intelligence projects
                            2025-03-18